Altay Therapeutics
Altay Therapeutics, Inc.
Pioneering the first oral drug for FSHD and advancing cancer treatment solutions.
altaytherapeutics.com · San Carlos, CA
Funding event
The round itself, as filedInferred stageSeries A
Sold of offered$15.7M of $45.1M
Filed2026-10-02
Days since filing1
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- Yes
- Date of first sale
- 2026-09-17
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- JAMES BREITMEYERExecutive Officer · Director
- ALI OZESExecutive Officer
- ERIC BJERKHOLTDirector
- MIKE GREYDirector
- ESTER SKLARSKYDirector
- AIDAN KINGDirector
- CHELSEA JOHNSONDirector
Health flags
Three flags, each with the raw inputs behind it · as of 2026-10-03UndersubscribedNot flagged34.9% sold0.5 months since first sale
Prior raiseNot flaggedPrior raise not known—
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-10-030
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
No open roles foundWe read careers pages daily.
Also raised in Health & bio
Same sector, 28 days to 2026-10-04CarebilitySeries A · $8.8M of $8.8M · Richardson, TXQuietCAD TherapeuticsSeed · $4.0M of $10.0M · New York, NYQuiet
75 rounds in Health & bio in the 28 days to 2026-10-02, against 71 in the 28 days before.